Incyte (INCY) Net Cash Flow Growth (5y) (2015 - 2026)
Incyte (INCY) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn |
| 10 | Incyte | 23.79 Bn | 19.78 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.12% |
| Dec 31, 2025 | 108.17% |
| Sep 30, 2025 | 24.25% |
| Jun 30, 2025 | -44.69% |
| Mar 31, 2025 | 18.35% |
| Dec 31, 2024 | 23.76% |
| Sep 30, 2024 | 2.10% |
| Jun 30, 2024 | -85.88% |
| Mar 31, 2024 | -0.34% |
| Dec 31, 2023 | -16.26% |
| Sep 30, 2023 | -12.66% |
| Jun 30, 2023 | 55.75% |
| Mar 31, 2023 | -91.19% |
| Dec 31, 2022 | 25.71% |
| Sep 30, 2022 | -17.81% |
| Jun 30, 2022 | 14.56% |
| Mar 31, 2022 | 21.84% |
| Dec 31, 2021 | 0.03% |
| Sep 30, 2021 | 17.04% |
| Jun 30, 2021 | 22.42% |